Tectonic Therapeutic, Inc. (TECX) research
Tectonic Therapeutic, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $24.12
- As of
Tectonic Therapeutic, Inc. (TECX): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-06.
As of . Source: SEC EDGAR filings for TECX. Method and limitations.
Share the TECX intelligence card
See TECX live in the terminal
Track TECX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live TECX terminal, freeActive signals for TECX
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +184% to TECX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +295% to TECX (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +61% to TECX (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +184% to TECX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +295% to TECX (2026Q2)
FREE, NO ACCOUNT
Every signal on TECX, as it fires
You are seeing 5 of 17 signals recorded on TECX since 2026-05-30.
The five above all landed on 2026-09-06. The other 12 were recorded on 4 other days. 13 of the 17 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TECX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 878972108 · 2026Q2 | $6.4M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 878972108 · 2026Q2 | $5.7M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 878972108 · 2026Q2 | $3.1M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TECX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
TECX against its peers
TECX's return on equity of -29.5% ranks in the 68th percentile of 19 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | TECX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 39.8M | n/a | 14 |
| Operating margin | n/a | -93.0% | n/a | 12 |
| Net margin | n/a | -120.0% | n/a | 12 |
| Return on equity | -29.5% | -50.5% | 68 | 19 |
Peers (20): CAPR, RGNX, OVID, ARVN, AUTL, KYTX, CTNM, ASMB, MPLT, PBYI, ENTX, OCS, PRME, EPRX, ALLO, CRMD, STTK, INDP, VALN, PHAT. Left out: VOGX (no annual filing), EIKN (no annual filing), DRUG (period gap), AGMB (no annual filing), SCTX (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (TECX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more TECX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to TECXand get the insider, 13F, options, and confluence read in one view.